Understanding the community impact of lymphatic filariasis: a review of the sociocultural literature.
Identifieur interne : 003589 ( PubMed/Corpus ); précédent : 003588; suivant : 003590Understanding the community impact of lymphatic filariasis: a review of the sociocultural literature.
Auteurs : Shona Wynd ; Wayne D. Melrose ; David N. Durrheim ; Jaime Carron ; Margaret GyapongSource :
- Bulletin of the World Health Organization [ 0042-9686 ] ; 2007.
English descriptors
- KwdEn :
- Albendazole (therapeutic use), Community Health Services (organization & administration), Cultural Characteristics, Diethylcarbamazine (therapeutic use), Drug Therapy, Combination, Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (psychology), Filaricides (administration & dosage), Filaricides (therapeutic use), Health Knowledge, Attitudes, Practice, Humans, Ivermectin (therapeutic use), Life Style, Prejudice.
- MESH :
- chemical , administration & dosage : Filaricides.
- chemical , therapeutic use : Albendazole, Diethylcarbamazine, Filaricides, Ivermectin.
- drug therapy : Elephantiasis, Filarial.
- organization & administration : Community Health Services.
- psychology : Elephantiasis, Filarial.
- Cultural Characteristics, Drug Therapy, Combination, Health Knowledge, Attitudes, Practice, Humans, Life Style, Prejudice.
Abstract
Lymphatic filariasis (LF) is endemic in approximately 80 tropical and subtropical countries. About 120 million people are infected with the parasite and a billion are estimated to be at risk of infection. The main focus of the LF elimination programme to date has been to interrupt transmission by means of annual community-wide treatment campaigns with diethylcarbamazine and albendazole, or albendazole and ivermectin, for a period of four to six years. Although substantial progress has been recorded wherever the strategy has been successfully implemented, initial gains have been accompanied by a realization that this strategy alone will not ensure a permanent solution in all settings. The fairly extensive LF literature is dominated by laboratory research and quantitative field measurement of the impact of LF, particularly local prevalence studies of parasite-infected humans and vectors. As the global elimination programme expands, the absence of sociocultural understanding is being recognized as a critical flaw in ensuring that programmes are appropriate and responsive to local needs and understanding. This paper assesses the current state of sociocultural understanding pertaining to LF. It concludes that, at present, there is insufficient understanding of the sociocultural factors associated with the presence and treatment of the disease, and that appropriate social science methods should be used to address this deficiency and ensure community partnership in delivering and sustaining the success of LF elimination programmes.
PubMed: 17639248
Links to Exploration step
pubmed:17639248Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Understanding the community impact of lymphatic filariasis: a review of the sociocultural literature.</title>
<author><name sortKey="Wynd, Shona" sort="Wynd, Shona" uniqKey="Wynd S" first="Shona" last="Wynd">Shona Wynd</name>
<affiliation><nlm:affiliation>Department for International Development, East Kilbride, United Kingdom.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Melrose, Wayne D" sort="Melrose, Wayne D" uniqKey="Melrose W" first="Wayne D" last="Melrose">Wayne D. Melrose</name>
</author>
<author><name sortKey="Durrheim, David N" sort="Durrheim, David N" uniqKey="Durrheim D" first="David N" last="Durrheim">David N. Durrheim</name>
</author>
<author><name sortKey="Carron, Jaime" sort="Carron, Jaime" uniqKey="Carron J" first="Jaime" last="Carron">Jaime Carron</name>
</author>
<author><name sortKey="Gyapong, Margaret" sort="Gyapong, Margaret" uniqKey="Gyapong M" first="Margaret" last="Gyapong">Margaret Gyapong</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2007">2007</date>
<idno type="RBID">pubmed:17639248</idno>
<idno type="pmid">17639248</idno>
<idno type="wicri:Area/PubMed/Corpus">003589</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003589</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Understanding the community impact of lymphatic filariasis: a review of the sociocultural literature.</title>
<author><name sortKey="Wynd, Shona" sort="Wynd, Shona" uniqKey="Wynd S" first="Shona" last="Wynd">Shona Wynd</name>
<affiliation><nlm:affiliation>Department for International Development, East Kilbride, United Kingdom.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Melrose, Wayne D" sort="Melrose, Wayne D" uniqKey="Melrose W" first="Wayne D" last="Melrose">Wayne D. Melrose</name>
</author>
<author><name sortKey="Durrheim, David N" sort="Durrheim, David N" uniqKey="Durrheim D" first="David N" last="Durrheim">David N. Durrheim</name>
</author>
<author><name sortKey="Carron, Jaime" sort="Carron, Jaime" uniqKey="Carron J" first="Jaime" last="Carron">Jaime Carron</name>
</author>
<author><name sortKey="Gyapong, Margaret" sort="Gyapong, Margaret" uniqKey="Gyapong M" first="Margaret" last="Gyapong">Margaret Gyapong</name>
</author>
</analytic>
<series><title level="j">Bulletin of the World Health Organization</title>
<idno type="ISSN">0042-9686</idno>
<imprint><date when="2007" type="published">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Albendazole (therapeutic use)</term>
<term>Community Health Services (organization & administration)</term>
<term>Cultural Characteristics</term>
<term>Diethylcarbamazine (therapeutic use)</term>
<term>Drug Therapy, Combination</term>
<term>Elephantiasis, Filarial (drug therapy)</term>
<term>Elephantiasis, Filarial (psychology)</term>
<term>Filaricides (administration & dosage)</term>
<term>Filaricides (therapeutic use)</term>
<term>Health Knowledge, Attitudes, Practice</term>
<term>Humans</term>
<term>Ivermectin (therapeutic use)</term>
<term>Life Style</term>
<term>Prejudice</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Filaricides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Albendazole</term>
<term>Diethylcarbamazine</term>
<term>Filaricides</term>
<term>Ivermectin</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" qualifier="organization & administration" xml:lang="en"><term>Community Health Services</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Cultural Characteristics</term>
<term>Drug Therapy, Combination</term>
<term>Health Knowledge, Attitudes, Practice</term>
<term>Humans</term>
<term>Life Style</term>
<term>Prejudice</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Lymphatic filariasis (LF) is endemic in approximately 80 tropical and subtropical countries. About 120 million people are infected with the parasite and a billion are estimated to be at risk of infection. The main focus of the LF elimination programme to date has been to interrupt transmission by means of annual community-wide treatment campaigns with diethylcarbamazine and albendazole, or albendazole and ivermectin, for a period of four to six years. Although substantial progress has been recorded wherever the strategy has been successfully implemented, initial gains have been accompanied by a realization that this strategy alone will not ensure a permanent solution in all settings. The fairly extensive LF literature is dominated by laboratory research and quantitative field measurement of the impact of LF, particularly local prevalence studies of parasite-infected humans and vectors. As the global elimination programme expands, the absence of sociocultural understanding is being recognized as a critical flaw in ensuring that programmes are appropriate and responsive to local needs and understanding. This paper assesses the current state of sociocultural understanding pertaining to LF. It concludes that, at present, there is insufficient understanding of the sociocultural factors associated with the presence and treatment of the disease, and that appropriate social science methods should be used to address this deficiency and ensure community partnership in delivering and sustaining the success of LF elimination programmes.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17639248</PMID>
<DateCreated><Year>2007</Year>
<Month>07</Month>
<Day>19</Day>
</DateCreated>
<DateCompleted><Year>2007</Year>
<Month>09</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised><Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0042-9686</ISSN>
<JournalIssue CitedMedium="Print"><Volume>85</Volume>
<Issue>6</Issue>
<PubDate><Year>2007</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Bulletin of the World Health Organization</Title>
<ISOAbbreviation>Bull. World Health Organ.</ISOAbbreviation>
</Journal>
<ArticleTitle>Understanding the community impact of lymphatic filariasis: a review of the sociocultural literature.</ArticleTitle>
<Pagination><MedlinePgn>493-8</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Lymphatic filariasis (LF) is endemic in approximately 80 tropical and subtropical countries. About 120 million people are infected with the parasite and a billion are estimated to be at risk of infection. The main focus of the LF elimination programme to date has been to interrupt transmission by means of annual community-wide treatment campaigns with diethylcarbamazine and albendazole, or albendazole and ivermectin, for a period of four to six years. Although substantial progress has been recorded wherever the strategy has been successfully implemented, initial gains have been accompanied by a realization that this strategy alone will not ensure a permanent solution in all settings. The fairly extensive LF literature is dominated by laboratory research and quantitative field measurement of the impact of LF, particularly local prevalence studies of parasite-infected humans and vectors. As the global elimination programme expands, the absence of sociocultural understanding is being recognized as a critical flaw in ensuring that programmes are appropriate and responsive to local needs and understanding. This paper assesses the current state of sociocultural understanding pertaining to LF. It concludes that, at present, there is insufficient understanding of the sociocultural factors associated with the presence and treatment of the disease, and that appropriate social science methods should be used to address this deficiency and ensure community partnership in delivering and sustaining the success of LF elimination programmes.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wynd</LastName>
<ForeName>Shona</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department for International Development, East Kilbride, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Melrose</LastName>
<ForeName>Wayne D</ForeName>
<Initials>WD</Initials>
</Author>
<Author ValidYN="Y"><LastName>Durrheim</LastName>
<ForeName>David N</ForeName>
<Initials>DN</Initials>
</Author>
<Author ValidYN="Y"><LastName>Carron</LastName>
<ForeName>Jaime</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Gyapong</LastName>
<ForeName>Margaret</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Switzerland</Country>
<MedlineTA>Bull World Health Organ</MedlineTA>
<NlmUniqueID>7507052</NlmUniqueID>
<ISSNLinking>0042-9686</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005369">Filaricides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>70288-86-7</RegistryNumber>
<NameOfSubstance UI="D007559">Ivermectin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>F4216019LN</RegistryNumber>
<NameOfSubstance UI="D015766">Albendazole</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>V867Q8X3ZD</RegistryNumber>
<NameOfSubstance UI="D004049">Diethylcarbamazine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Trans R Soc Trop Med Hyg. 1999 Jul-Aug;93(4):413-7</RefSource>
<PMID Version="1">10674092</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS Med. 2005 Nov;2(11):e336</RefSource>
<PMID Version="1">16212468</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Acta Trop. 2000 Dec 1;77(3):287-94</RefSource>
<PMID Version="1">11114391</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Trop Med Parasitol. 2001 Jan;95(1):77-86</RefSource>
<PMID Version="1">11235557</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2001 Mar;6(3):190-5</RefSource>
<PMID Version="1">11299035</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2001 Aug;6(8):582-606</RefSource>
<PMID Version="1">11555425</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2002 Jan;7(1):59-69</RefSource>
<PMID Version="1">11851956</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Bull World Health Organ. 2002;80(3):251-2</RefSource>
<PMID Version="1">11984613</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Qual Health Res. 2002 Dec;12(10):1427-39</RefSource>
<PMID Version="1">12474913</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2003 Jan;8(1):56-9</RefSource>
<PMID Version="1">12535251</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Trop Doct. 2003 Apr;33(2):79-82</RefSource>
<PMID Version="1">12680538</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Trop Med Parasitol. 2003 Dec;97(8):839-45</RefSource>
<PMID Version="1">14754496</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Soc Sci Med. 2004 Aug;59(3):501-23</RefSource>
<PMID Version="1">15144761</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Bull World Health Organ. 1979;57(4):499-512</RefSource>
<PMID Version="1">316733</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Trans R Soc Trop Med Hyg. 1979;73(4):424-6</RefSource>
<PMID Version="1">45325</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Southeast Asian J Trop Med Public Health. 1986 Sep;17(3):457-63</RefSource>
<PMID Version="1">3563614</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Southeast Asian J Trop Med Public Health. 1986 Sep;17(3):479-85</RefSource>
<PMID Version="1">3551094</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Southeast Asian J Trop Med Public Health. 1988 Jun;19(2):207-14</RefSource>
<PMID Version="1">2906482</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Soc Sci Med. 1992 Sep;35(5):627-45; discussion 645-9</RefSource>
<PMID Version="1">1359648</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>World Health Organ Tech Rep Ser. 1992;821:1-71</RefSource>
<PMID Version="1">1441569</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Acta Trop. 1993 Mar;53(1):1-26</RefSource>
<PMID Version="1">8096106</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Med J Aust. 1993 Apr 5;158(7):465-9</RefSource>
<PMID Version="1">8469196</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Acta Trop. 1996 Apr;61(2):79-92</RefSource>
<PMID Version="1">8740887</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Soc Sci Med. 1996 May;42(10):1401-10</RefSource>
<PMID Version="1">8735896</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 1996 Aug;1(4):433-8</RefSource>
<PMID Version="1">8765449</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Soc Sci Med. 1995 Dec;41(12):1705-13</RefSource>
<PMID Version="1">8746870</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Soc Sci Med. 1996 Jul;43(2):235-42</RefSource>
<PMID Version="1">8844927</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Acta Trop. 1997 Jan;63(1):57-60</RefSource>
<PMID Version="1">9083585</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Bull World Health Organ. 1997;75(6):491-503</RefSource>
<PMID Version="1">9509621</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 1998 Jun;3(6):467-73</RefSource>
<PMID Version="1">9657509</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Trop Med Hyg. 1957 May;6(3):402-14; discussion, 415</RefSource>
<PMID Version="1">13435415</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2005 Jun;10(6):567-73</RefSource>
<PMID Version="1">15941420</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2000 Sep;5(9):591-4</RefSource>
<PMID Version="1">11044272</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D015766" MajorTopicYN="N">Albendazole</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003153" MajorTopicYN="N">Community Health Services</DescriptorName>
<QualifierName UI="Q000458" MajorTopicYN="Y">organization & administration</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003466" MajorTopicYN="N">Cultural Characteristics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004049" MajorTopicYN="N">Diethylcarbamazine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005369" MajorTopicYN="N">Filaricides</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007722" MajorTopicYN="N">Health Knowledge, Attitudes, Practice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007559" MajorTopicYN="N">Ivermectin</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008019" MajorTopicYN="N">Life Style</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011287" MajorTopicYN="N">Prejudice</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>43</NumberOfReferences>
<OtherID Source="NLM">PMC2636343</OtherID>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year>
<Month>02</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2006</Year>
<Month>12</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2007</Year>
<Month>7</Month>
<Day>20</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2007</Year>
<Month>9</Month>
<Day>14</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2007</Year>
<Month>7</Month>
<Day>20</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">17639248</ArticleId>
<ArticleId IdType="pii">S0042-96862007000600017</ArticleId>
<ArticleId IdType="pmc">PMC2636343</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003589 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003589 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:17639248 |texte= Understanding the community impact of lymphatic filariasis: a review of the sociocultural literature. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:17639248" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
This area was generated with Dilib version V0.6.31. |